AZN Share PerformanceMore
|52 week high||5,505 05/08/16|
|52 week low||3,680 24/06/16|
|52 week change||907 (21.47%)|
|4 week volume||47,237,312 31/08/16|
Latest News« previous» nextMore
26/09/2016 - 16:00 RNS
RNS Number: 8429K AstraZeneca PLC 26 September 2016 26 September 2016 16:00 Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 26 September 2016, the interest of Sean Bohen, a person discharging managerial responsibilities, in the ordinary shares of AstraZeneca PLC changed as detailed below. The change in interest rela...
22/09/2016 - 14:18 Interactive Investor
Shell hasn't cut the dividend since WW2, but these fund managers think it will have to. Lee Wild finds out why they've sol...
22/09/2016 - 11:00 RNS
RNS Number: 5617K AstraZeneca PLC 22 September 2016 22 September 2016 11.00 New external board appointment Listing Rule LR 9.6.14 R (2) Ann Cairns, a Non-Executive Director of AstraZeneca PLC, is expected to join the Board of Directors of Intercontinental Exchange, Inc., a company listed on the New York Stock Exchange, effective from 2017. About AstraZ...
14/09/2016 - 14:30 StockMarketWire
Societe Generale today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and set its price target at 7000...
14/09/2016 - 11:00 StockMarketWire
Exane BNP Paribas today downgrades its investment rating on AstraZeneca PLC (LON:AZN) to neutral (from outperform...
13/09/2016 - 14:40 StockMarketWire
Liberum Capital today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and set its price target at 520...
12/09/2016 - 11:17 Motley Fool
Life science research tool supplier Abcam (LSE:ABC) has released an upbeat set of full year results. They show that the com...
12/09/2016 - 08:50 StockMarketWire
Jefferies International today upgrades its investment rating on AstraZeneca PLC (LON:AZN) to buy (from hold) and raise...
Latest discussion posts More
“Reinvested some of the cash from ARM shares in AZN because of generally progressive yield currently around 3.7%, forecast 4.2%, also improved SP performance over the last year. ...”▼
“"AstraZeneca dodged a London market sell-off on Monday on optimism that potential blockbusters in its cancer drugs pipeline can revive earnings growth. Jefferies, ...”▼
“From ADVFN: "Jefferies upgraded AstraZeneca to 'buy' from 'hold' and lifted the price target to 5,800p from 5,400p saying it sees a much higher probability of success and ...”▼
Codes & Symbols
|Symbols||AZN, LSE:AZN, AZN.L, AZN:LN, LON:AZN, XLON:AZN|